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Effect of anticoagulation on blood membrane interactions dur- in the extracorporeal circuit and to improve biocompati-
ing hemodialysis. bility of artificial membranes. While unfractionated hep-
Background. Adequate anticoagulation is a precondition to arin (UFH) has been widely used, it is associated withprevent extracorporeal blood clotting and to improve biocom-
several disadvantages, such as an increase in bleedingpatibility during hemodialysis. In this study, we performed a
risk, consumption of antithrombin III, but also an activa-morphologic analysis by using scanning electron microscopy
to compare three modes of anticoagulation—conventional un- tion of platelets and neutrophils, which may negatively
fractionated heparin (UFH), low molecular weight heparin affect the biocompatibility of the extracorporeal circuit.
(LMWH; dalteparin sodium), or sodium citrate during hemodi- Moreover, because of its short half-life, a priming dosealysis—on membrane-associated coagulation activation.
alone is often not enough to ensure the anticoagulationMethods. Fifteen patients on regular hemodialysis therapy
throughout the hemodialysis session. Alternatively, lowwere investigated. Five patients received UFH, five patients
LMWH, and five patients sodium citrate as an anticoagulant molecular weight heparins (LMWHs) have a longer half-
during a standardized hemodialysis protocol using a single-use life and have been reported to induce less bleeding, less
polysulfone capillary dialyzer. Membrane-associated clotting
consumption of antithrombin III, and a lower proaggreg-was evaluated using a scanning electron microscope. A dialyzer
atory effect on platelets [1, 2].clotting score was used for quantitative description of coagula-
tion activation on membrane segments. In recent years, sodium citrate has gained more popu-
Results. Using UFH as an anticoagulant revealed the most larity as an anticoagulant during hemodialysis, especially
pronounced cell adhesion and thrombus formation and the in patients with increased bleeding risks, because of the
highest dialyzer clotting score (11.5 6 1.3 of a maximal 20
advantages of an efficient anticoagulation that is exclu-points). LMWH had a lower dialyzer clotting score than UFH
sively confined to the extracorporeal circulation and also(10.4 6 1.2 of 20 points). During the use of sodium citrate, a
negligible thrombus formation and the lowest dialyzer clotting an improvement of the biocompatibility by inhibition of
score (1.6 6 0.6 of 20 points, P , 0.05) were observed. activation of blood cells [3].
Conclusion. The results of this investigation indicate that In this study, we used a scanning electron microscopicusing sodium citrate as an anticoagulant during hemodialysis
(SEM) analysis to compare three different anticoagula-induces a lower activation of coagulation than both conven-
tion regimes—conventional UFH, LMWH, and sodiumtional and fractionated heparin, which might contribute to an
improvement of biocompatibility of hemodialysis extracorpo- citrate—to investigate the morphology of thrombus for-
real circulation. mation and cellular aggregation on the interior surfaces
of hemodialysis membranes.
Adequate anticoagulation is a precondition for any
METHODSeffective hemodialysis therapy both to prevent clotting
Patients and hemodialysis therapy
Fifteen patients (median age 39 6 11 years) on regularKey words: blood coagulation, dialysis, clotting, heparin, cell adhesion,
thrombosis. hemodialysis therapy were included in this investigation.
Patient characteristics are shown in Table 1. The studyReceived for publication November 17, 1998
was approved by the local institutional review board,and in revised form May 13, 1999
Accepted for publication May 18, 1999 and patients gave informed consent.
A standardized hemodialysis protocol was followed 1999 by the International Society of Nephrology
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Table 1. Patient characteristics glutaraldehyde in a 0.04 m sodium cacodylate buffer (pH
7.4), rinsed three times with PBS, and dehydrated in aUFH LMWH SCA
graded ethanol series. The samples were critical pointAge 2869 33 611 3067
Sex distribution male:female 3:2 2:3 1:4 dried and gold sputtered. Then the specimens were ex-
Body weight kg 58616 61 613 57614 amined with a JOEL 6310 scanning electron microscope
Primary disease 4 GN 5 GN 4 GN
(JOEL, Tokyo, Japan) at an accelerated voltage of 5 to1 ATN 1 ATN
15 kV [4].Patients were treated by three types of anticoagulation during hemodialysis
therapy: unfractionated heparin (UFH), low molecular weight heparin (LMWH),
and sodium citrate anticoagulation (SCA). Abbreviations are: GN, glomerulone- Dialyzer clotting score
phritis; ATN, acute tubulointerstitial nephritis.
A scoring system for semiquantitative description of
the clotting activation on the internal surfaces of the
dialyzer membrane was employed. Five items were ana-
during all treatments: A single-use hollow fiber hemodi- lyzed on a scale of 0 (minimum) to 4 points (maximum):
alysis membrane [polysulfone high performance steam, fiber surface area involved by thrombus formation, fibrin
Hemoflow F8 HPSe; Fresenius, Bad Homburg, Ger- net formation, erythrocyte aggregate formation, involve-
many (N 5 15)] was used. Blood flow was adjusted to ment of platelets in aggregate formation, and obstruction
250 ml/min, and the dialysis duration was four hours. of the lumen. The reference area was assessed from the
Patients were allocated to three treatment groups of geometric presets of the dialyzer fibers. The scores in
anticoagulation. In the first group, five patients received each item were added up to a “total dialyzer clotting
conventional UFH from porcine mucosa (Heparin Im- score” (DCS).
munoe; Baxter-Immuno, Vienna, Austria). A bolus in-
jection of 1000 U was followed by a constant infusion Statistical analysis
of 1000 U/hr. In the second group, five patients received The statistical evaluation was done using the SAS soft-
LMWH dalteparin sodium (Fragmine; Pharmacia, Upp- ware (SAS Institute Inc., Cary, NC, USA). Data were
sala, Sweden), a 85 U/kg body wt as bolus before the start
analyzed nonparametrically by means of the Tukey
of hemodialysis therapy. In the last group, five patients
range comparison. Results are expressed as mean 6 sd.received sodium citrate (0.5 mol/liter; Mayerhofer Phar-
maceuticals Inc., Linz, Austria), a rate of 50 mmol/hr
into the arterial blood line and calcium chloride (0.5 RESULTS
mol/liter; Mayerhofer Pharmaceuticals Inc.) at a rate Coagulation activations on the fibers of the dialyzers
of approximately 10 mmol/hr into the venous line to are illustrated by Figures 1 to 3. These scanning electron
maintain an ionized calcium concentration of approxi- micrographs show the inner surfaces of the sample fibers
mately 1.1 mmol/liter. During citrate anticoagulation, of the dialyzers investigated. Coagulation activation on
the sodium and bicarbonate concentration in the dialy-
the fibers of the dialyzers is illustrated in Figure 1. A
sate was reduced. Patients did not receive other drugs
fibrin network with large amounts of aggregated erythro-affecting coagulation and/or platelets.
cytes, a red thrombus formation covering a high portionHemodialysis membranes were removed at the end of
of the fiber surface and protruding into the fiber lumen, isthe dialysis session and were gently rinsed with normal
evident in these micrographs. Similar observations weresaline to clean the inside of the membrane capillaries.
made in the dialyzers obtained from the other four pa-Within 10 minutes after removal, the hemodialysis mem-
tients.branes were prepared for SEM analysis.
Figure 2 shows the inner surface of the capillary fiber
when LMWH has been used as anticoagulant duringScanning electron microscopy
hemodialysis. A stronger fibrin network with erythro-For SEM analysis, the hemodialysis membranes were
cytes is evident in these images, but a much lower numberopened, and the fibers were removed and were care-
of erythrocytes are involved in the thrombus formation.fully cut longitudinally using a binocular microscope
A lower surface area is covered, and there is now major(SMZUe; Nikon, Tokyo, Japan) at a magnification of
obstruction of the fiber lumen. Several platelets can be40 times. Then the fiber fragments were twice gently
identified in this figure. Again, similar findings were dem-flushed with phosphate-buffered saline (PBS). Flushing
onstrated in dialyzers obtained from the other four pa-was standardized as follows: A 50 ml syringe was con-
tients with LMWH anticoagulation.nected to the tube of the dialysis membrane. Three flushes
Figure 3 shows the findings on the inner surface of awere done on each membrane, with each flushing period
capillary dialyzer when the patient received sodium ci-lasting for 60 seconds. The flusher was not aware of the
trate as the anticoagulant. Only a few single cells adher-patients and their regimens because the membranes were
blinded. Then the fiber fragments were fixed in 2.5% ing to the inner surface were observed. No thrombus
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formation was seen, and no fibrin network could be
found (Fig. 3).
The semiquantitative evaluation using the DCS is
given in Table 2. With UFH as anticoagulant during
hemodialysis therapy, a total score of 11.5 6 1.3 out of
a maximum of 20 points was obtained. The total DCS
using LMWH was 10.4 6 1.2 points. In dialyzers with
sodium citrate anticoagulation, the total DCS was only
1.6 6 0.6 points (P , 0.05 vs. UFH and LMWH).
DISCUSSION
In a morphological analysis using a SEM evaluation
of the inner surfaces of polysulfone hollow fiber dialyzer
membranes, we compared three types of anticoagulation
during hemodialysis therapy. The degree of coagulation
activation was highest during the use of conventional
UFH, lesser during LMWH, and virtually absent during
the use of sodium citrate.
The clotting mechanism is a cascade of proenzyme-
enzyme transformations, each activating the next until
the final substrate, fibrinogen, is reached. Each factor in
the coagulation cascade is short lived, only a matter of
a few seconds, terminating with the rapid conversion of
fibrinogen into fibrin, the main component of thrombus.
The generation of clot-promoting activity by artificial
surfaces depends on the activation of the Hageman or
surface factor XII, which initiates and triggers a series
of enzymatic reactions culminating in the generation of
thrombin and the formation of fibrin. All of the elements
of the blood, including platelets, fibrin, erythrocytes, and
leukocytes, may enter into the formation of a thrombus.
The three most important factors in the generation of a
thrombus include slowing the blood flow in the blood
circulation, changes in the blood vessel wall, changes
in the blood, and the biocompatibility of the artificial
membranes, respectively. Heparin, endogenously syn-
thesized from the liver and mast cells, helps to maintain
the fluidity of the blood in the systemic circulation. Hepa-
rin, newer small molecular weight heparins, and other
glycosaminoglycans prevent the aggregations of platelets
to form platelet thrombi [5–10]. Heparin, an acid with
a pH of 6.93, enhances or potentates antithrombin III
(ATIII) and neutralizes the action of thrombin, thus
preventing the formation of a fibrin clot. ATIII also
binds to factors IXa, Xa, XIa, and XIIa. Under normal
circumstances, the binding of ATIII to thrombin and the
other activated factors of the intrinsic pathway occurs
slowly. In the presence of heparin, the rate of ATIII
Fig. 1. Scanning electron micrographs of the inner surface of a polysul- binding is accelerated. Without ATIII, heparin has al-
fone hollow fiber dialyzer membrane using heparin as anticoagulant
most no anticoagulant action. The endothelial locationduring hemodialysis therapy. (A) Overview showing a dense fibrin
network with large amounts of aggregated erythrocytes. (B) Pseudo- of heparin sulfate permits binding and activation of
membraneous formation (magnification of lower frame in panel A) of ATIII at the blood–surface interface, where activated
aggregated erythrocytes. (C) Magnification of aggregated erythrocytes
factors of the coagulation cascade are being generated.(magnification of upper frame in panel A). Similar observations were
made in the dialyzers obtained from the other patients. A number of studies have demonstrated the impor-
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Fig. 2. Scanning electron micrographs of the inner surface of a polysulfone hollow fiber dialyzer membrane using low molecular weight heparin
as anticoagulant during hemodialysis therapy. (A–C) A stronger fibrin network is shown, but much less erythrocytes. (D) A platelet in a fibrin
network using a high magnification. Similar observations were made in the dialyzers obtained from the other four patients.
tance of UFH and LMWH in modulating thrombus gen- cuit demonstrated that the use of a heparin-coated circuit
did not reduce thrombin generation [13–14].eration. LMWHs may be preferable to UFHs in the
prevention of thromboembolism in general surgery [11]. Coagulation activation is obviously one of the most
important barriers to adequacy of dialysis delivery. Re-LMWHs have been shown to be as effective and safe
as intravenous UFH in patients with acute pulmonary cently, Shegal et al analyzed patient-related and techni-
cal factors determining dialysis delivery in 1836 treat-embolism [12]. Heparinization of materials and medical
devices can alter thrombogenicity. An in vitro study by ments provided to 721 randomly selected patients on
regular hemodialysis therapy [16]. Their study concludedEngbers et al reported that with polyurethane catheters,
the adhesion of platelets onto the catheter surface is that besides dialysis prescription, problems with vascular
access and clotting are the most important limits to dial-mainly determined by the rate of reaction between plate-
lets and the material surface. Heparin-coated catheters ysis adequacy.
Coagulation activation presents one of the main deter-showed a fourfold to fivefold reduction in platelet adhe-
sion as compared with noncoated catheters. However, minants of biocompatibility. Clotting not only reduces
the efficiency of dialysis therapy by mechanical obstruc-in a Scandinavian study, a comparison of thrombin gen-
eration during cardiopulmonary bypass with heparin- tion of the dialysis membrane, but causes activation of
other cascade systems such as the complement system,coated versus conventional cardiopulmonary bypass cir-
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Table 2. Dialyzer clotting score (DCS) of a polysulfone hollow fiber
dialysis membrane during three types of anticoagulation during
hemodialysis therapy: unfractionated heparin (UFH), low
molecular weight heparin (LMWH), and sodium citrate
anticoagulation (SCA)
UFH LMWH SCA
Surface area involved 3.2 60.4 2.4 60.2 0.8 60.2a
Fibrin net formation 1 60.3 2.460.4 0 60a
Involvement of erythrocytes 3.6 60.2 2.4 60.2 0.8 60.4a
Involvement of platelets 0.8 60.2 1.6 60.2 0 60a
Obstruction of fiber lumen 3.8 60.2 1.6 60.2 0 60a
Total “DCS” 11.5 61.3 10.4 61.2 1.6 60.6a
a P , 0.05
such as an improvement in lipid metabolism, less activa-
tion of platelets, and less consumption of antithrombin
III. Whether or not LMWHs—as frequently claimed—in
fact reduce bleeding complications was not uniformly
confirmed.
The lowest degree of clotting formation on the dialyzer
membrane was observed when using sodium citrate as
the anticoagulant. Citrate anticoagulation in hemodialy-
sis therapy has become popular, especially for patients
with a high risk for bleeding, because the anticoagulatory
effect is exclusively confined to the extracorporeal blood
volume with no coagulation alterations in the systemic
circulation. Moreover, it is inexpensive and easy to de-
liver. The most important advantage besides the superb
anticoagulatory effect is the improvement in the overall
biocompatibility of the extracorporeal circuit during ci-
trate anticoagulation. Calcium ions are not only required
for blood coagulation, but are also a prerequisite for any
cellular activation, such as of thrombocytes and neutro-
Fig. 3. Scanning electron micrographs of the inner surface of a polysul- phils. Boehler et al have convincingly demonstrated that
fone hollow fiber dialyzer membrane using sodium citrate as anticoagu-
during citrate anticoagulation the release of proteolyticlant during hemodialysis therapy. Only a few single cells adhering to
the inner surface were observed. No thrombus formation was seen. enzymes from neutrophils is, in fact, abolished [3].
Similar observations were made in the dialyzers obtained from the Unfortunately, few studies are available comparing
other four patients.
citrate with conventional means of anticoagulation. Jans-
sen et al have compared 21 dialysis patients receiving the
LMWH nadroparin calcium or sodium citrate. Analyzing
the activated clotting time, activated partial thrombo-activation of cellular elements besides platelets and espe-
plastin time, factor anti-Xa, and prothrombin, these au-cially polymorphonuclear neutrophils, the release of va-
thors found that in contrast to citrate, LMWH inducedsoactive hormones, such as thromboxane, of mediators
systemic anticoagulation during hemodialysis [18–21].such as tumor necrosis factor a and enzymes such as
In summary, the results of this morphological studyelastase.
using a SEM analysis, in which various anticoagulationThe extent of clotting was most pronounced during
regimes during hemodialysis therapy were comparedanticoagulation with conventional UFH at a recom-
with respect to coagulation activation on a polysulfonemended dosage [17]. Therapy with UFH is associated
membrane hollow fiber, showed that clotting activationwith several additional disadvantages, which may aggra-
was most pronounced during conventional UFH heparin,vate the bioincompatibility and provide a proaggregatory
less prominent during LMWH, and virtually absent dur-effect on platelets and activation of neutrophils. During
ing sodium citrate anticoagulation. Besides this optimalLMWH coagulation, activation was much less pronounced
anticoagulatory effect, sodium citrate has additional ad-than with UFH. LMWHs have pharmacokinetic advan-
vantages such as the strictly regional nature of anticoagu-tages with sufficient anticoagulation for up to six hours
after a single initial bolus injection, metabolic advantages lation and a superior effect on biocompatibility. Sodium
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